Jci_page_head_homepage_01 Jci_page_head_homepage_02
Antoine Muchir, Paul Pavlidis, Valérie Decostre, Alan J. Herron, Takuro Arimura, Gisèle Bonne, Howard J. Worman
Published in Volume 117, Issue 5
J Clin Invest. 2007; 117(5):1282–1293 doi:10.1172/JCI29042
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 3
MAPK signaling is activated in hearts and isolated cardiomyocytes from Lmna H222P mice.

(A) Detection of phosphorylated JNK (pJNK) and ERK1/2 (pERK1/2) in hearts and isolated cardiomyocytes from Lmna+/+, LmnaH222P/+, and LmnaH222P/H222P mice. JNK and ERK1/2 were measured by immunoblotting with Abs against total protein (JNK and ERK1/2) and phosphoprotein (pJNK and pERK1/2). Data in bar graphs are mean ± SD of 5 samples per group (*P < 0.05, ***P < 0.0005). (B) Effect of MAPK activation on downstream targets in Lmna+/+, LmnaH222P/+, and LmnaH222P/H222P mice. Representative immunoblots using Abs that recognize phosphorylated c-Jun (pc-Jun), Elk1, and bcl-2 and β-tubulin as a loading control are shown for proteins extracted from heart tissue and isolated ventricular cardiomyocytes.